10x Genomics (TXG)
(Delayed Data from NSDQ)
$13.49 USD
+0.13 (0.97%)
Updated Nov 5, 2025 04:00 PM ET
After-Market: $13.60 +0.11 (0.82%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
TXG 13.49 +0.13(0.97%)
Will TXG be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for TXG based on the 1-3 month trading system that more than doubles the S&P 500.

Zacks News for TXG
10x Genomics (TXG) Upgraded to Buy: Here's Why
TXG: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for TXG
Cathie Wood Pours into Veracyte Stake ahead of Earnings Beat, Slashes Biotech Holdings
Is TXG positioned for a breakout? Stochastic Reached Overbought shows up after dropping 2.48%
Torex Gold Reports Strong Q3 2025 Results, Returns to Positive Cash Flow
Vanguard Group Inc's Strategic Acquisition of 10x Genomics Inc Shares
Earnings Scheduled For November 5, 2025